JP2015517512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517512A5 JP2015517512A5 JP2015512053A JP2015512053A JP2015517512A5 JP 2015517512 A5 JP2015517512 A5 JP 2015517512A5 JP 2015512053 A JP2015512053 A JP 2015512053A JP 2015512053 A JP2015512053 A JP 2015512053A JP 2015517512 A5 JP2015517512 A5 JP 2015517512A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- lymphoma
- cell
- seq
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 19
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 19
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 8
- 229960002707 bendamustine Drugs 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 230000036210 malignancy Effects 0.000 claims 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 6
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 5
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 208000003950 B-cell lymphoma Diseases 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 208000010566 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000009606 gray zone lymphoma Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 230000002871 immunocytoma Effects 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000003393 splenic effect Effects 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 230000001573 trophoblastic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12168397 | 2012-05-16 | ||
| EP12168397.3 | 2012-05-16 | ||
| PCT/EP2013/060101 WO2013171289A1 (en) | 2012-05-16 | 2013-05-15 | Combination of cd37 antibodies with further agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015517512A JP2015517512A (ja) | 2015-06-22 |
| JP2015517512A5 true JP2015517512A5 (OSRAM) | 2016-06-30 |
Family
ID=48446355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512053A Pending JP2015517512A (ja) | 2012-05-16 | 2013-05-15 | Ｃｄ３７抗体の更なる薬剤との併用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20130309224A1 (OSRAM) |
| EP (1) | EP2849783A1 (OSRAM) |
| JP (1) | JP2015517512A (OSRAM) |
| WO (1) | WO2013171289A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| CN106046159B (zh) | 2010-03-12 | 2020-06-16 | 德彪发姆国际有限公司 | Cd37结合分子及其免疫缀合物 |
| JP2015516980A (ja) * | 2012-04-26 | 2015-06-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とベンダムスチンとの併用 |
| US8992915B2 (en) | 2012-05-16 | 2015-03-31 | Boehringer Ingelheim International Gmbh | Combination of CD37 antibodies with ICE |
| US20160101199A1 (en) | 2013-06-07 | 2016-04-14 | Nordic Nanovector As | Method for upregulating antigen expression |
| WO2015116729A2 (en) * | 2014-01-28 | 2015-08-06 | Emergent Product Development Seattle, Llc | Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders |
| CA2986437A1 (en) | 2015-06-08 | 2016-12-15 | Debiopharm International, S.A. | Anti-cd37 immunoconjugate and anti-cd20 antibody combinations |
| WO2017040247A1 (en) | 2015-08-28 | 2017-03-09 | Immunogen, Inc. | Antibodies and assays for detection of cd37 |
| WO2018083633A1 (en) | 2016-11-02 | 2018-05-11 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
| MX2020012755A (es) | 2018-05-30 | 2021-02-26 | Debiopharm Int Sa | Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37). |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| DE19911329A1 (de) | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
| CA2388063C (en) | 1999-11-24 | 2010-06-08 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
| CA2395660A1 (en) | 1999-12-29 | 2001-07-12 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| CN1816356A (zh) | 2003-05-14 | 2006-08-09 | 免疫原公司 | 药物缀合物组合物 |
| US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| SI1912675T1 (sl) * | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| SG189772A1 (en) * | 2008-04-11 | 2013-05-31 | Trubion Pharmaceuticals Inc | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| JP2015516980A (ja) * | 2012-04-26 | 2015-06-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とベンダムスチンとの併用 |
-
2013
- 2013-05-15 EP EP13723136.1A patent/EP2849783A1/en not_active Withdrawn
- 2013-05-15 JP JP2015512053A patent/JP2015517512A/ja active Pending
- 2013-05-15 WO PCT/EP2013/060101 patent/WO2013171289A1/en not_active Ceased
- 2013-05-15 US US13/894,738 patent/US20130309224A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517512A5 (OSRAM) | ||
| JP2012515217A5 (OSRAM) | ||
| RU2019138710A (ru) | Антитела, специфичные к flt3, и их применения | |
| JP6114273B2 (ja) | 抗−ｃｄ１９抗体とプリン類似体の併用治療 | |
| JP2015517511A5 (OSRAM) | ||
| FI3988117T3 (fi) | Terapeuttiset vasta-aineet ja niiden käyttö | |
| JP2018524347A5 (OSRAM) | ||
| JP2017507954A5 (OSRAM) | ||
| JP2017517488A5 (OSRAM) | ||
| FI3500299T3 (fi) | Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa | |
| JP2019506403A5 (OSRAM) | ||
| JP2013518086A5 (OSRAM) | ||
| Tanasescu et al. | Advances in the treatment of relapsing-remitting multiple sclerosis | |
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| JP2019517485A5 (OSRAM) | ||
| JP2016536314A5 (OSRAM) | ||
| JP2015534577A5 (OSRAM) | ||
| JP2013538790A5 (OSRAM) | ||
| Blaszczak et al. | Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma | |
| JP6184952B2 (ja) | 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法 | |
| JP2014525925A5 (OSRAM) | ||
| WO2016189014A1 (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| JP2022137089A (ja) | 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用 | |
| JP2019533682A5 (OSRAM) | ||
| FI3464380T3 (fi) | Gp100-spesifisen tcr-anti-cd3 scfv-fuusioproteiinin annosteluohjelma |